Long-term performance of the hemodialysis reliable outflow (HeRO) device: the 56-month follow-up of the first clinical trial patient.
The Hemodialysis Reliable Outflow (HeRO) Vascular Access Device is a novel long-term subcutaneous dialysis graft, ideally suited for catheter-dependent patients and patients dialyzing with failing fistulas or grafts due to venous outflow stenosis. This case presentation depicts the clinical course of the first patient to enter a Food and Drug Administration approved clinical trial and receive the HeRO device. The course of this patient over 56 months of follow-up provides the longest experience with the HeRO device to-date. In this patient, the HeRO device provided long-term dialysis access patency in conjunction with adequate dialysis and a low intervention rate.
Nassar
George M
GM
Nephrology, Dialysis, and Transplantation Associates, Department of Internal Medicine, Weill Cornell University at the Methodist Hospital, Houston, TX, USA. gnassar@kidneydocs.org
D000368:Aged; D001132:Arm / Q000098:blood supply*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation*; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000295:instrumentation*; D002408:Catheters, Indwelling / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D011138:Polytetrafluoroethylene; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000295:instrumentation*; D016896:Treatment Outcome; D014654:Vascular Patency
D011138:Polytetrafluoroethylene